Care of patients with non-small-cell lung cancer stage III- the Central European real-world experience

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602442" target="_blank" >RIV/61989592:15110/20:73602442 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/20:00115905 RIV/00216208:11110/20:10411821 RIV/00064203:_____/20:10411821 RIV/00064190:_____/20:N0000063

Result on the web

<a href="https://content.sciendo.com/view/journals/raon/54/2/article-p209.xml" target="_blank" >https://content.sciendo.com/view/journals/raon/54/2/article-p209.xml</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2478/raon-2020-0026" target="_blank" >10.2478/raon-2020-0026</a>

Result language

angličtina

Original language name

Care of patients with non-small-cell lung cancer stage III- the Central European real-world experience

Original language description

Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. The real-world study demonstrated a broad heterogeneity in the management o f stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30203 - Respiratory systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Radiology and Oncology

ISSN

1318-2099

e-ISSN

—

Volume of the periodical

54

Issue of the periodical within the volume

2

Country of publishing house

SI - SLOVENIA

Number of pages

12

Pages from-to

209-220

UT code for WoS article

000537450400008

EID of the result in the Scopus database

2-s2.0-85085630493